来源: Pharmaceutical Technology
At the Advanced Therapies Conference, experts discussed the current pharmaceutical investment landscape. Credit: ktasimar via Shutterstock
Investment rounds and fundraising will likely take longer given the crowded landscape of companies wanting to raise funds, say investors. “Most investors have a big stack of funds to look at, and more things to look at than they have time,” said Robert Balfour PhD, an investment director at Alsa Ventures. Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
来源: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will receive an email shortly. Please check for download the Report.
Go deeper with GlobalData
来源: Pharmaceutical Technology
ReportsFuture of Pharma - Looking Ahead to 2023
来源: Pharmaceutical Technology
The gold standard of business intelligence.
Related Company ProfilesKinnate Biopharma IncView all
At the ongoing Advanced Therapies 2024 conference, being held 19-20 March in London, experts at an investor-focused panel discussed the current state of early-stage investment in biotech and pharma. Balfour explained that previously, upon receiving an email from a company seeking investment, he would be able to respond within two to three weeks. But now the waiting time has been extended as investors lack bandwidth. “There has been a downturn in the market as a lot of companies are fundraising, so every investor has a lot of choice,” he added.
In order to stand out, “The first thing I want to see is science,” said Paola Pozzi, a partner at Soffinova Partners. She explained that with a stronger science-backed platform, early-stage companies improve the chances of increasing the values of their initial public offerings (IPOs), which is even more important in a “poor biotech ecosystem”.
Apart from the science, Dominic O’Regan an investor at the life sciences consultancy New Mosaic, declared that at the early stages, it is important for biotechs to establish where its assets may fit within specific indications and show clarity on where they may fit in the landscape in the next three to four years.
GlobalData reports that private biotech venture financing dipped in 2023, showing a reduction of 43.2% when compared to 2022, and a 52.3% drop in comparison to 2021. This amongst other factors saw several pharmaceutical companies cut down operations to fund their lead assets. For example, Neximmune removed over half of its staff in September and Kinnate Biopharma followed, laying off 70% of its workforce, in the same month. Ascendis Pharma files patent for ocular drug delivery system using cross-linked Ha 来源: Pharmaceutical Technology
Purdue Pharma files patent for purifying noroxymorphone by preparing and isolating bisulfite adduct 来源: Pharmaceutical Technology
Despite the previously difficult funding environment, GlobalData predicts that there may be a shift in investor sentiment. In GlobalData’s Thematic Intelligence report, “The State of the Biopharmaceutical Industry 2024,” the company found that 44% of healthcare professionals surveyed globally are optimistic or very optimistic about biotech funding recovery in the next 12 months.
Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
来源: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will receive an email shortly. Please check for download the Report.